Global Multilayer Co-extruded Film Infusion Bags Market to Reach $2.34 Billion by 2031, Growing at 3.9% CAGR

Multilayer Co-extruded Film Infusion Bags: Definition and Principles

Multilayer co-extruded film infusion bags are non-PVC containers formed by co-extruding multiple polymer layers in a single continuous process to create a flexible, sealed bag for the containment and delivery of intravenous (IV) fluids, biologics, parenteral nutrition, and other sterile liquid pharmaceuticals. Unlike traditional infusion bags made from polyvinyl chloride (PVC) that require plasticizers (e.g., DEHP, DINP, etc.) to impart flexibility, multilayer co-extruded films use alternative polymers — such as polyethylene (PE), polypropylene (PP), ethylene-vinyl acetate (EVA), cyclic olefin copolymer (COC), ethylene-vinyl alcohol (EVOH), and polyamide (PA) — to achieve the required flexibility, barrier properties, and chemical stability without the need for toxic additives.

Key design features and performance characteristics:

• Multilayer structure: A typical co-extruded film may consist of 3–7 layers, each serving a specific function:

  • Inner contact layer (product-contact layer): Made of ultra-pure, biocompatible polymers (usually PE or PP) that are inert to drug formulations, ensuring no leaching or adsorption of active pharmaceutical ingredients.

  • Barrier layer: EVOH or other high-barrier polymers to prevent oxygen and moisture ingress, extending the shelf life of sensitive drugs and reducing oxidation/degradation.

  • Outer layer: Durable, heat-sealable polymers (PE, PP, or polyester) that provide mechanical strength, puncture resistance, and heat-sealing performance.

  • Tie layers: Adhesive or compatibilizing layers that bond dissimilar polymers together, ensuring delamination-free performance.

• Excellent oxygen and moisture barrier: Protects oxygen-sensitive drugs (e.g., antibiotics, vitamins, biologics, chemotherapy agents) from degradation and maintains solution integrity.

• Chemical stability and inertness: No leaching of plasticizers, monomers, or other extractables into the drug solution (unlike PVC, which can leach DEHP and other additives), ensuring drug purity and patient safety.

• Heat-sealing performance: Enables secure, leak-proof sealing of the bag's edges and ports using high-frequency or heat-sealing equipment.

• Transparency: Enables visual inspection of the contents (color, clarity, particulate matter) by healthcare professionals.

• Lightweight and shatter-resistant: Compared to glass bottles, infusion bags are lighter (reducing shipping costs, improving ergonomics), shatter-resistant (reducing breakage and waste), and easier to store.

• Non-PVC composition: Free from DEHP and other phthalate plasticizers — reducing patient exposure to potentially harmful endocrine-disrupting compounds — and compatible with hospital incineration and recycling programs (when designed with mono-polymer or compatible materials).

• Compatibility with sensitive drug therapies: Can be used with biologics, monoclonal antibodies, chemotherapy agents, parenteral nutrition, and other high-value, unstable drugs.

Common applications:

1. Intravenous (IV) fluids: Saline, dextrose, Ringer's lactate, potassium chloride solutions, electrolyte replacement.

2. Parenteral nutrition: Total parenteral nutrition (TPN) and partial parenteral nutrition (PPN) — lipid emulsions, amino acids, vitamins, trace elements.

3. Drug delivery: Antibiotics, antivirals, anti-inflammatory drugs, chemotherapy agents.

4. Biologics and blood products: Immunoglobulins, monoclonal antibodies, blood fractions.

5. Irrigation solutions: Surgical irrigation, wound irrigation.

6. Dialysis solutions: Peritoneal dialysis and hemodialysis fluids.

Multilayer Co-extruded Film Infusion Bags Market Summary

According to a new market research report published by Market Monitor Global, the global Multilayer Co-extruded Film Infusion Bags market is projected to reach USD 2.34 billion by 2031, at a compound annual growth rate (CAGR) of 3.9% during the forecast period. This steady growth is driven by the replacement of traditional PVC infusion bags (due to DEHP/plasticizer health concerns and regulatory pressures), the shift from glass containers to flexible bags (improved safety, reduced weight, better cost-effectiveness), the aging global population, increasing prevalence of chronic diseases requiring intravenous therapies, and the growing demand for advanced packaging for biologics and sensitive drug formulations.

Market Monitor Global's analysis indicates that the global key manufacturers of Multilayer Co-extruded Film Infusion Bags include Baxter (USA), Fresenius Kabi (Germany), B. Braun (Germany), Sichuan Kelun Pharmaceutical (China), and ICU Medical (USA). In 2024, the global top five players collectively accounted for approximately 67.0% of total revenue, indicating a moderately concentrated market with a few large multinational players dominating the premium and established markets, and a growing presence of regional players (particularly Chinese manufacturers) serving local or price-sensitive segments.

In terms of product type (by bag capacity), the 250ml segment is currently the largest, holding a 49.1% share. This size is the most commonly used for standard intravenous fluids, drug infusions, and many parenteral therapies. 500ml and 1000ml bags are also significant, used for larger-volume infusions, blood products, and specific hydration therapies. Smaller sizes (50ml, 100ml) are used in pediatric applications, specialty drug delivery, and certain biologics. The segmentation by capacity reflects the diversity of patient needs and clinical applications.

Regarding application, Hospitals is the largest segment, accounting for 82.1% of the market. Inpatient settings use infusion bags extensively for: post-surgical hydration, medication delivery, emergency department fluid resuscitation, ICU therapy, chemotherapy, parenteral nutrition, and dialysis. Clinics and Outpatient Care (approximately 10-12%) and Home Healthcare (approximately 5-8%) are the fastest-growing segments, driven by the trend of "hospital at home," home-based parenteral nutrition, and self-administration of chronic therapies. Ambulatory Surgical Centers and Other applications account for the remainder.

Regional dynamics: Asia-Pacific is the largest consumer of Multilayer Co-extruded Film Infusion Bags, with a market share of more than 43% in 2024, driven by China's large healthcare sector (Sichuan Kelun being a major player), expanding hospital capacity, aging population, and government healthcare investment. Europe is the second-largest market, with approximately 35% share, driven by stringent regulations on PVC/DEHP (EU's RoHS and REACH), high healthcare standards, and strong presence of major players (Fresenius Kabi, B. Braun). North America (US and Canada) is the third-largest market, with the US being a significant consumer of infusion therapies, driven by an aging population, advanced healthcare infrastructure, and regulatory action against DEHP. The Rest of the World (including Latin America, Middle East, Africa, and Southeast Asia) represents smaller but growing markets.

Multilayer Co-extruded Film Infusion Bags Market Dynamics

Market Drivers:

• D1: Regulatory pressure to phase out PVC and DEHP – The primary driver for the shift from PVC to multilayer co-extruded films is regulation. DEHP (di(2-ethylhexyl) phthalate) — a plasticizer used to make PVC flexible — is a suspected endocrine disruptor, reproductive toxicant, and has been associated with adverse effects in vulnerable populations (neonates, children, pregnant women, and patients receiving long-term infusions). Regulatory actions include:

  • EU: The Medical Device Regulation (MDR) and REACH regulations restrict DEHP in medical devices; many EU hospitals have banned or are phasing out PVC-containing devices.

  • US: FDA has issued guidance on DEHP in medical devices, especially for pediatric and neonatal use; many US healthcare systems have adopted DEHP-free policies.

  • China: The National Medical Products Administration (NMPA) has encouraged the use of non-PVC infusion containers; many Chinese hospitals prefer non-PVC bags.

  • Other countries: Similar regulatory and policy measures in Japan, South Korea, Australia, and Canada.
    These regulations create a strong market demand for DEHP-free, non-PVC infusion bags.

• D2: Aging population and rising prevalence of chronic diseases – Global demographics are shifting toward older populations. By 2030, the number of people aged 60+ is projected to reach 1.4 billion (from 1 billion in 2020). Older adults have higher rates of:

  • Cardiovascular diseases: Congestive heart failure, cardiac arrhythmias, hypertension — requiring IV medications and fluids.

  • Renal diseases: Chronic kidney disease, end-stage renal disease — requiring IV fluids, electrolyte replacement, dialysis solutions.

  • Metabolic disorders: Diabetes, electrolyte imbalances — requiring IV insulin, fluids, and electrolyte therapy.

  • Cancer: Chemotherapy requiring IV infusion bags (often non-PVC due to drug compatibility).

  • Gastrointestinal diseases: Malabsorption, inflammatory bowel disease — requiring parenteral nutrition.
    As the global population ages and chronic disease prevalence rises, hospital admissions, surgical procedures, and long-term IV therapy increase, driving demand for infusion bags.

• D3: Replacement of PVC and glass containers – Infusion therapy has traditionally relied on:

  • PVC bags: Flexible, cheap, but contain DEHP plasticizers that leach into fluids (especially lipid-based fluids, blood products, and certain drugs). Also, PVC requires incineration (releasing dioxins) or ends up in landfills with slow degradation.

  • Glass bottles: Historically used for IV fluids, but are heavy, breakable, expensive to ship, require more storage space, and can introduce particulate matter (glass shards, rubber stopper particles) into solutions.
    Multilayer co-extruded film bags offer:

  • No DEHP or phthalates — patient safety improvement.

  • Shatterproof, lightweight, stackable — reduces shipping costs, storage space, and waste.

  • Recyclability (when designed as mono-polymer or compatible materials) — environmental benefits.

  • Better compatibility with oxygen-sensitive and UV-sensitive drugs — improved shelf life.
    These advantages drive the replacement of both PVC bags and glass bottles globally, particularly in modern healthcare systems.

• D4: Growing demand for biologics, biosimilars, and personalized medicines – The biotechnology revolution is accelerating the development of complex, high-value therapies:

  • Monoclonal antibodies: Used in oncology, immunology, infectious diseases.

  • Biosimilars: Lower-cost versions of biologic drugs.

  • Gene therapies and cell therapies: CAR-T, gene-editing therapies.

  • Personalized medicines: Tailored to individual patient genetics or biomarkers.
    These therapies are often:

  • Unstable in solution: Sensitive to oxygen, light, temperature, and pH changes.

  • High value: Very expensive per dose ($1,000–$500,000+ per treatment).

  • Require specific packaging: Compatible with the drug formulation, minimizing adsorption, leaching, and degradation.
    Multilayer co-extruded films provide the exceptional barrier integrity, chemical inertness, and compatibility needed for these advanced therapies, making them essential for modern drug delivery systems. As biologics and biosimilars proliferate, demand for high-performance infusion bags grows.

• D5: Shift toward home healthcare and outpatient infusion – Healthcare systems globally are shifting from inpatient to outpatient, ambulatory, and home-based care to reduce costs, improve patient convenience, and reduce hospital-acquired infections. Home infusion therapies include:

  • Parenteral nutrition: For patients with short bowel syndrome, Crohn's disease, or gastrointestinal disorders.

  • IV antibiotics: For chronic infections (osteomyelitis, endocarditis).

  • Chemotherapy: For cancer patients receiving long-term or palliative treatment at home.

  • Immunoglobulin (IVIG) therapy: For immunodeficiency disorders, autoimmune diseases.

  • Hydration therapy: For patients with chronic dehydration or electrolyte imbalances.
    Home infusion requires:

  • User-friendly packaging: Easy to open, handle, and administer.

  • Integrated hangers: For drip stands or IV poles.

  • Simplified ports: For easy connection and disconnection.

  • Robust packaging: For shipping and storage at home.
    Multilayer film bags are well-suited for home care due to their lightweight, shatterproof, and user-friendly design.

Market Restraints:

• R1: Higher manufacturing cost compared to PVC bags – Multilayer co-extruded film infusion bags are more expensive to manufacture than PVC bags due to:

  • More complex multilayer extrusion process (requires co-extrusion equipment, precise layer thickness control, multiple polymer feed systems).

  • Higher-cost raw materials: Polyolefins (PE, PP), EVOH, COC, and other engineering polymers are generally more expensive than PVC resin.

  • Specialized equipment: Co-extrusion lines require significant capital investment and technical expertise.

  • R&D and regulatory costs: FDA, EU MDR, and NMPA approval for new non-PVC bag designs requires extensive testing (extractables/leachables, biocompatibility, shelf-life studies, sterility validation).
    This higher cost can be a barrier in price-sensitive markets (e.g., developing countries, cash-strapped healthcare systems) and can limit adoption where PVC bags remain acceptable or where cost is the primary consideration.

• R2: Complex regulatory compliance and validation – Infusion bags are Class II or Class III medical devices, requiring regulatory clearance (FDA 510(k) or PMA, CE marking under MDR, NMPA approval). Key regulatory challenges:

  • Extractables and leachables (E&L) testing: Proving that the bag does not leach harmful substances into the drug solution requires extensive, complex, and expensive testing.

  • Shelf-life and stability studies: Demonstrating that the bag maintains sterility and drug integrity over the product's shelf life (typically 1-3 years) requires time-consuming, costly testing.

  • Drug compatibility testing: Each new drug or drug formulation may require separate compatibility testing with the bag.

  • Sterilization validation: Infusion bags are typically sterilized by autoclaving (steam) or gamma irradiation; both must be validated to ensure sterility without degrading the film or its properties.
    The regulatory burden is significant and can delay new product launches, increase costs, and limit innovation, especially for smaller manufacturers.

• R3: Recycling and environmental challenges – While non-PVC films are an environmental improvement over PVC (reducing dioxin releases and phthalate concerns), they still create plastic waste. Key challenges:

  • Mixed polymer structures: Multilayer films contain multiple different polymers (PE, PP, EVOH, tie layers, etc.), making recycling difficult (requires separation). Some newer designs use mono-polymer (all-PE or all-PP) bags to improve recyclability, but these are more expensive and have less proven performance.

  • Medical waste classification: Used infusion bags are classified as healthcare waste (often incinerated or autoclaved before disposal), which can contaminate recycling streams.

  • Lack of established collection and recycling infrastructure: Even if the film is technically recyclable, few facilities are equipped to collect, sort, and recycle used medical plastic waste.

  • Regulatory pressure: The EU's Single-Use Plastics Directive and other regulations are increasing pressure on manufacturers to improve recyclability or reduce plastic consumption.
    Manufacturers face the challenge of balancing performance, cost, and recyclability in new product designs.

Market Opportunities:

• O1: Development of mono-polymer (all-PE or all-PP) recyclable bags – To address recycling challenges, manufacturers are developing mono-polymer infusion bags made entirely from a single polymer family (e.g., all-polyethylene or all-polypropylene). Advantages:

  • Improved recyclability: Can be recycled in existing polyolefin recycling streams (no need for separation).

  • Simpler material supply: Reduced raw material complexity.

  • Lower regulatory burden (extractables/leachables): Fewer materials to assess and qualify.

  • Sustainability marketing: Appeals to environmentally conscious healthcare systems.
    While mono-polymer bags are still under development (and may require compromises on barrier properties or mechanical performance), early adopters can gain a competitive advantage in sustainability-focused markets (e.g., EU, leading US health systems).

• O2: Smart infusion bags with integrated sensors – Real-time monitoring features are being embedded into infusion bags:

  • Temperature sensors: Monitor bag temperature during storage and transport; alert if temperature goes out of range (critical for biologics and temperature-sensitive drugs).

  • Tamper-evident and anti-counterfeit features: RFID or NFC tags embedded in the bag to ensure authenticity and prevent tampering.

  • Fluid level monitoring: Sensors to detect when the bag is empty or when flow has stopped, improving patient safety and reducing "air in line" alarms.

  • Barcode/QR tracking: For supply chain traceability, batch and lot tracking, and automated inventory management.
    Smart packaging improves patient safety, supply chain traceability, and operational efficiency in pharmaceutical applications. Manufacturers that integrate sensing capabilities into bag designs can create differentiated, higher-margin products.

• O3: Expansion in emerging markets (India, Southeast Asia, Latin America, Africa) – Healthcare infrastructure is expanding rapidly in emerging economies:

  • India: Government health spending is rising, private hospitals are growing, and demand for safe infusion systems is increasing with urbanization and chronic disease prevalence.

  • Southeast Asia: Indonesia, Vietnam, Philippines, Thailand — all experiencing rising healthcare demand and improving hospital standards.

  • Latin America: Brazil, Mexico, Argentina, Chile — growing healthcare systems with increasing penetration of advanced medical technologies.

  • Africa: Rapid urbanization and growing healthcare investment (particularly in South Africa, Nigeria, Kenya, Egypt).
    Manufacturers can penetrate these markets through:

  • Local manufacturing partnerships (to reduce costs, improve supply chain resilience, and gain regulatory approval).

  • Lower-cost product lines (standard non-PVC bags, basic configurations, reduced complexity).

  • Government and NGO partnerships (to supply public hospitals and health programs).

  • Training and technical support (to ensure proper use and patient safety).
    The growth potential in emerging markets is substantial, given the current low penetration of non-PVC bags in many of these regions.

• O4: Development of bespoke bags for biologics and advanced therapies – The rapid expansion of biologics, biosimilars, and personalized medicines creates opportunities for bespoke, drug-specific infusion bags:

  • Biologics: Often require specific packaging materials to avoid protein adsorption, precipitation, or denaturation.

  • Chemotherapy drugs: Some are highly reactive, requiring specialized inner layer materials (e.g., fluoropolymer-coated bags) to prevent drug adsorption and ensure accurate dosing.

  • Cell and gene therapies: Require ultraclean, certified materials to avoid contamination; may require specialized port designs for aseptic transfer.

  • High-value drugs: For treatments costing $10,000+ per dose, the incremental cost of specialized infusion bags is negligible, and hospitals/pharmacies are willing to pay for premium packaging.
    Manufacturers that can offer custom-designed bags — tailored to specific drugs, with validated compatibility data and dedicated production lines — can capture high-margin, stable demand from pharmaceutical companies.

• O5: Lightweighting and material reduction – Sustainability pressure is driving demand for thinner, lighter infusion bags that use less material without compromising performance. Benefits:

  • Reduced material costs: Less plastic per bag.

  • Reduced shipping weight: Lower transportation costs and carbon footprint.

  • Reduced waste: Less plastic to dispose of after use.

  • Compliance with packaging reduction targets: EU packaging directives and corporate sustainability goals.
    Lightweighting requires careful engineering to maintain barrier properties, mechanical strength, and heat-seal integrity. Manufacturers that can achieve significant lightweighting (10-20% reduction in film thickness or weight) while maintaining performance can differentiate on cost and sustainability.

• O6: Trade friction and import substitution — localization of supply – The ongoing US-China trade friction and broader geopolitical tensions have encouraged import substitution and localization of medical device supply chains. Key trends:

  • US: The Biden administration's emphasis on "Buy American" and supply chain resilience for medical devices has encouraged domestic manufacturing of infusion bags and films.

  • EU: Similarly, European health authorities and hospitals are increasingly sourcing from local manufacturers to ensure supply chain security.

  • China: China's "Made in China 2025" and its post-COVID emphasis on reducing dependence on foreign medical supplies have driven domestic investment in multilayer film production.

  • India: Government's "Make in India" and Production Linked Incentive (PLI) schemes encourage local manufacturing of medical devices.
    Manufacturers that can localize production in key markets — through new facilities, acquisitions, or partnerships — can benefit from favorable regulatory and procurement policies, reduce shipping costs and lead times, and respond more quickly to local customer needs.

Industry Structure and Competitive Dynamics

The global Multilayer Co-extruded Film Infusion Bags market is characterized by:

• Global leaders (Baxter, Fresenius Kabi, B. Braun): These multinationals have strong R&D, regulatory expertise, extensive product portfolios, global manufacturing and distribution networks, and long-standing relationships with hospitals, healthcare systems, and government procurement agencies. They lead in premium, high-quality, and differentiated products (biologics-compatible, custom designs, smart packaging).

• Regional leaders (Sichuan Kelun Pharmaceutical in China; ICU Medical in the US; others): These players dominate their respective domestic markets, often through lower cost structures, strong local relationships, and understanding of regional regulatory requirements. Many are expanding regionally and globally.

• Emerging players: Numerous smaller and medium-sized manufacturers — particularly in China, India, and Southeast Asia — are entering the market with cost-competitive standard products, targeting domestic or regional demand. They offer lower prices but may lack the regulatory approvals and quality track record of the multinationals for premium applications.

Key success factors in this market:

• Regulatory expertise (FDA, EU MDR, NMPA, other approvals) and compliance capabilities.

• Product quality and consistency (batch-to-batch reliability, sterile integrity, barrier performance).

• Cost competitiveness (raw material sourcing, manufacturing efficiency, supply chain optimization).

• Application expertise (understanding clinical needs, drug compatibility, and healthcare trends).

• Sustainability credentials (recyclable materials, reduced environmental footprint, "green" marketing).

• Customer relationships (long-term contracts with hospitals, group purchasing organizations, pharmaceutical companies).